This study aimed to evaluate Ellorarxine’s RAR subtype selectivity and the ability of Ellorarxine to ameliorate a range of pathophysiological mechanisms in the three key cell types in the mammalian brain, namely neurons, glia and microglia, relevant to neurodegenerative disease without adverse effects. The gene discussed is RARA; the disease is neurodegenerative disease.